RT Journal Article
SR Electronic
T1 Should recombinant human growth hormone therapy be used in short small for gestational age children?
JF Archives of Disease in Childhood
JO Arch Dis Child
FD BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health
SP 740
OP 744
DO 10.1136/adc.2003.034785
VO 89
IS 8
A1 L B Johnston
A1 M O Savage
YR 2004
UL http://adc.bmj.com/content/89/8/740.abstract
AB Short small for gestational age (SGA) children represent 20% of all children with short stature1 and therefore constitute a significant portion of the caseload in a growth clinic. The recent approval of recombinant human growth hormone (GH) for the treatment of short stature in SGA children by the European Union’s Committee on Proprietary Medicinal Products offers a new licensed therapeutic option. This article examines the role of GH therapy in short SGA children with particular reference to selection of patients, effectiveness, safety, and its potential metabolic implications.